Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7915MR)

This product GTTS-WQ7915MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7915MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9247MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ14736MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ1498MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ4655MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ5735MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ6697MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ1071MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ993MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW